KR20150023404A - 체중 감소 방법 - Google Patents

체중 감소 방법 Download PDF

Info

Publication number
KR20150023404A
KR20150023404A KR20147035499A KR20147035499A KR20150023404A KR 20150023404 A KR20150023404 A KR 20150023404A KR 20147035499 A KR20147035499 A KR 20147035499A KR 20147035499 A KR20147035499 A KR 20147035499A KR 20150023404 A KR20150023404 A KR 20150023404A
Authority
KR
South Korea
Prior art keywords
methazolamide
patient
treatment
diabetes
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147035499A
Other languages
English (en)
Korean (ko)
Inventor
켄 웰더
가이 크립너
제프 니콜슨
Original Assignee
베바 파마슈티칼스 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베바 파마슈티칼스 엘티디 filed Critical 베바 파마슈티칼스 엘티디
Publication of KR20150023404A publication Critical patent/KR20150023404A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR20147035499A 2012-05-24 2013-03-15 체중 감소 방법 Withdrawn KR20150023404A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US61/651,335 2012-05-24
PCT/AU2013/000259 WO2013173858A1 (en) 2012-05-24 2013-03-15 A method of weight reduction

Publications (1)

Publication Number Publication Date
KR20150023404A true KR20150023404A (ko) 2015-03-05

Family

ID=49622926

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147035499A Withdrawn KR20150023404A (ko) 2012-05-24 2013-03-15 체중 감소 방법

Country Status (16)

Country Link
US (2) US20150174108A1 (enExample)
EP (1) EP2854806A4 (enExample)
JP (1) JP6438389B2 (enExample)
KR (1) KR20150023404A (enExample)
CN (1) CN104582701B (enExample)
AU (1) AU2013202981B2 (enExample)
BR (1) BR112014029302A2 (enExample)
CA (1) CA2874512A1 (enExample)
CO (1) CO7160083A2 (enExample)
HK (1) HK1209041A1 (enExample)
MX (1) MX2014014316A (enExample)
NZ (1) NZ702666A (enExample)
RU (1) RU2664442C2 (enExample)
SG (1) SG11201407786XA (enExample)
WO (1) WO2013173858A1 (enExample)
ZA (1) ZA201408703B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801375B (zh) 2007-01-25 2014-01-01 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法
WO2013173859A1 (en) * 2012-05-24 2013-11-28 Verva Pharmaceuticals Ltd A method of improving liver function
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE60110087T2 (de) * 2000-08-11 2005-09-29 Einar Stefansson Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
CN100415224C (zh) * 2003-03-18 2008-09-03 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
DE602004012403T2 (de) * 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
WO2007114948A2 (en) * 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
CN101801375B (zh) * 2007-01-25 2014-01-01 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法
TW201105338A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
EP2585097B1 (en) * 2010-06-25 2018-09-26 Aston University Glycoproteins having lipid mobilizing properties and therapeutic uses thereof
EP2583965B1 (en) * 2010-07-15 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic ring compound
WO2013173859A1 (en) * 2012-05-24 2013-11-28 Verva Pharmaceuticals Ltd A method of improving liver function

Also Published As

Publication number Publication date
ZA201408703B (en) 2018-07-25
MX2014014316A (es) 2015-07-06
WO2013173858A1 (en) 2013-11-28
CA2874512A1 (en) 2013-11-28
JP6438389B2 (ja) 2018-12-12
US20180333398A1 (en) 2018-11-22
NZ702666A (en) 2016-08-26
CN104582701A (zh) 2015-04-29
CN104582701B (zh) 2018-01-16
JP2015520759A (ja) 2015-07-23
SG11201407786XA (en) 2015-03-30
CO7160083A2 (es) 2015-01-15
US20150174108A1 (en) 2015-06-25
AU2013202981A1 (en) 2013-12-12
EP2854806A4 (en) 2015-11-18
RU2014150946A (ru) 2016-07-10
EP2854806A1 (en) 2015-04-08
HK1209041A1 (en) 2016-03-24
AU2013202981B2 (en) 2014-11-13
RU2664442C2 (ru) 2018-08-17
BR112014029302A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
CN1960735B (zh) 药物组合在治疗胰岛素抗性中的应用
US8017633B2 (en) Roflumilast for the treatment of diabetes mellitus
CN101511364A (zh) 用于糖尿病的治疗组合
KR20120016051A (ko) 제약 조성물
US20070004623A1 (en) Use of hydroxylated amino acids for treating diabetes
US20180333398A1 (en) Method of weight reduction
KR101701943B1 (ko) 당뇨병의 치료 또는 예방약
JP6412241B2 (ja) 肝機能改善法
ITMI20002019A1 (it) Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
AU2016206292B2 (en) A method of improving liver function
KR100709531B1 (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
WO2012133693A1 (ja) 糖尿病治療用の組合せ医薬
JP2017128545A (ja) 併用医薬
Neerjesh et al. Spotlight on pharmacology of a noble oral hypoglycaemic agent: Metformin
HK1137345A (en) Combination treatment for diabetes mellitus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180309

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20190121

WITB Written withdrawal of application